Recent News

• 11.06.2026 - Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
• 11.06.2026 - Immunocore reports third quarter financial results and provides a business update
• 10.29.2026 - Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
• 10.15.2026 - Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
• 09.14.2026 - Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
• 09.01.2026 - Immunocore to present at upcoming investor conferences
• 08.06.2026 - Immunocore reports second quarter financial results and provides a business update
• 07.30.2026 - Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
• 05.31.2026 - Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
• 05.06.2026 - Immunocore reports first quarter financial results and provides a business update

Recent Filings

• 11.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2026 - 8-K Current report
• 11.06.2026 - EX-99.1 EX-99.1
• 10.07.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.14.2026 - 8-K Current report
• 09.14.2026 - EX-99.1 EX-99.1
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]